Qurient Co., Ltd. (KOSDAQ:115180)

Market Cap	297.42B
Revenue (ttm)	9.18B
Net Income (ttm)	-23.57B
Shares Out	34.23M
EPS (ttm)	-752.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	406,100
Average Volume	362,650
Open	6,750.00
Previous Close	6,750.00
Day's Range	6,200.00 - 7,280.00
52-Week Range	3,200.00 - 7,690.00
Beta	0.46
RSI	69.64
Earnings Date	Mar 20, 2025

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2024, Qurient's revenue was 9.18 billion, an increase of 1.64% compared to the previous year's 9.03 billion. Losses were -23.57 billion, 11.6% more than in 2023.